An Observational Study to Evaluate Patient-Reported Experiences of Living With Moderate-to-Severe Plaque Psoriasis

Launched by JANSSEN BIOTECH, INC. · Mar 14, 2012

Keywords

ClinConnect Summary

This study is planned with the primary objective of developing a database containing patient-reported information that may be used to understand and increase awareness of the impact that moderate-to-severe plaque psoriasis can have on both daily life and life in general from a patient's perspective. This is a multicenter observational (no drug given to the patient) patient narrative study. The duration of study is 16 weeks and includes adult patients with moderate-to-severe plaque psoriasis who are candidates for phototherapy or systemic therapy. The study investigators are dermatologists w...

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Adult male and female patients having diagnosis of plaque psoriasis for at least 6 months prior to screening
• • Patients who are candidates for or are currently receiving the following: a. conventional systemic agents (eg, MTX, acitretin, cyclosporine, fumarates, or systemic psoralens plus ultraviolet A light \[PUVA\]), b. topical therapy and/or phototherapy (and are eligible for, but are not currently receiving oral systemic or biologic therapy), c. biologic therapy for moderate to severe plaque psoriasis
• • Have a peak historical or current physician's global assessment (PGA) of greater than or equal to 3 (range 0-5)
• • Patients must have the ability to read and speak English
• • Patients must reside in the US.
• Exclusion Criteria:
• • Patients with guttate, erythrodermic, or pustular psoriasis (all are various types of psoriasis)
• • - Patients with serious concomitant illness that could require the use of systemic corticosteroids or otherwise interfere with the patient's participation in the trial